Despite the plethora of empirical studies conducted to date, debate continues about whether
and to what extent results should be returned to participants of genomic research. We aimed …

With the development of next generation sequencing, beyond identifying the cause of
manifestations that justified prescription of the test, other information with potential interest …

Background Data on the modalities of disclosing genomic secondary findings (SFs) remain
scarce. We explore cancer patients' and the general public's perspectives about disclosing …

Advances in genome sequencing together with the introduction of personalized medicine
offer promising new avenues for research and precision treatment, particularly in the field of …

In the middle of growing consensus that genomics researchers should offer to return
clinically valid, medically relevant, and medically actionable findings identified in the course …

The therapeutic use of genomic sequencing creates novel and unresolved questions about
cost, clinical efficacy, access, and the disclosure of sequencing results. The disclosure of the …

Whilst the underlying principles of precision medicine are comparable across the globe,
genomic references, health practices, costs and discrimination policies differ in Asian …

BACKGROUND Molecular testing to inform treatment and clinical trial choices is now the
standard of care for several types of cancer. However, no established guidelines exist for the …

Objectives: Genomic information will increasingly be used to aid in the prevention,
diagnosis, and treatment of disease. Several national initiatives are paving the way for this …

Genome sequencing (GS) studies involving healthy children can advance scientific
knowledge of genetic variation. Little research has examined primary care providers' views …